Slide 1: POLARIS-101 Next Gen Muscle Tropic AAV
POLARIS-101 Next Gen Muscle Tropic AAV Solid Bio, Shaping the Future of Gene Therapy © 2026 Solid Biosciences – Non-Confidential
Slide 2: POLARIS-101 is a Next-Generation Capsid With Improved Muscle Tropism
POLARIS-101 is a Next-Generation Capsid With Improved Muscle Tropism, Enabling Safe and Effective Systemic Administration POLARIS-101 offers potential for transformative efficiency with effective skeletal muscle and cardiac tissue targeting and lower toxicity risks High-efficiency transduction enabl
Slide 3: Solid's AAV Gene Therapy Development Kit Available for Partnership
Accelerating Innovation: Solid’s AAV Gene Therapy Development Kit Available for Partnership GROWING BODY OF ROBUST LEADING-EDGE CLINICAL DATA PRECLINICAL DATA CMC TECHNOLOGY Muscle biopsies at Mouse: Biodistribution POLARIS-101 RepCap Day 90 and Day 360 and expression in plasmid provided free of in
Slide 4: POLARIS-101: A Novel Capsid Showing Promising Clinical Signals in Duchenne
POLARIS-101 : A Novel Capsid Showing Promising Clinical Signals in Duchenne Muscular Dystrophy SGT-003 Solid’s next-gen, investigational microdystrophin gene transfer therapy that uses POLARIS-101 INSPIRE DUCHENNE Phase 1/2 Clinical Study Overview Heart • Single 1.0×1014 vg/kg IV dose of SGT-003 Ove
Slide 5: POLARIS-101 Enhances Muscle Targeting Through Multivalent RGD Motif
POLARIS-101 Enhances Muscle Targeting Through Novel Integration of a Multivalent RGD Motif1,2 POLARIS-101 Proposed Mechanism of Action POLARIS-101 was engineered to include an RGD motif inserted into the R Basal lamina Integrin VR-VIII loop of AAV9, resulting in up to G D 60 copies of the peptide di
Slide 6: Higher Skeletal and Cardiac Muscle Biodistribution vs AAV9 in Mouse and NHPs
POLARIS-101 Shows Higher Skeletal and Cardiac Muscle Biodistribution vs AAV9 in Mouse and NHPs Biodistribution in Isolated Tissues Biodistribution in Isolated Tissues (Day 28 Post-dose)a (Day 28 Post-dose)b POLARIS-101 AAV9 POLARIS-101 AAV9 QUADRICEPS HEART SKELETAL MUSCLE CARDIAC MUSCLE 3.7x 6.6x 2
Slide 7: High-Efficiency Expression vs AAV9 in NHPs and Human Cardiomyocytes
POLARIS-101 Demonstrates High-Efficiency Expression vs AAV9 in NHPs and Human Cardiomyocytes Expression Efficiency Expression Efficiency (Luciferase Activity in NHPs)a,b (Luciferase Activity In Vitro) POLARIS-101 AAV9 POLARIS-101 AAV9 SKELETAL MUSCLE CARDIAC MUSCLE HUMAN DUCHENNE HEALTHY iPSC-DERIVE
Slide 8: Human Phase 1/2 INSPIRE DUCHENNE Trial Supports Preclinical Data
Human Phase 1/2 INSPIRE DUCHENNE Trial Supports Preclinical Data Showing Reduced Liver Biodistribution of POLARIS-101 AAV Biodistribution to Liver POLARIS-101 AAV9 Liver Biomarkers in Participants Dosed Using POLARIS-101 b,c Fold Change vs AAV9 Fold Change vs AAV9 2.0 1.5 ALT AST GGT 1.5 1.0 150 750
Slide 9: Enhanced Kinetics Enabling Rapid Expression and Optimal Clearance Timing
POLARIS-101 Exhibits Enhanced Kinetics Enabling Rapid Expression vs AAV9 and AAVrh74 and Optimal Clearance Timing Luciferase Activity (Whole Body IVIS) Mean Clearance of POLARIS-101TM1 Total Flux (p/s)/µg) Days post-dose POLARIS-101 expression detected 2 days post-dose, Rapid clearance of POLARIS-10
Slide 10: Greater Protein Expression vs AAVrh74 in NHPs
POLARIS-101 Leads to Greater Protein Expression vs AAVrh74 in NHPs Expression Efficiency (LCMS - CK8-Microdystrophin in NHPs) Dose 1.0×1014 vg/kg1,a POLARIS-101 AAV9 HEARTb QUADRICEPSb 6x 5 4x 6 5 Fold Change vs AAV9 Fold Change vs AAV9 4 4 3 3 2 2 1 1 0 0 POLARIS-101 AAV-SLB101 AAVrh74 POLARIS-101
Slide 11: Redosing Potential: Low NAb Titers After AAVrh74 Dosing
Redosing Potential: POLARIS-101 Demonstrates Low NAb Titers After AAVrh74 Dosing in Multiple Species Assessment of NAbs After AAVrh74 Dosing Longitudinal Assessment Day 30 Assessment of NAb Titers in Humans Dosed With of POLARIS-101 NAbs after rh74 POLARIS-101 NAbs after AAVrh74 Days posttreatment t
Slide 12: Solid's Manufacturing Platform
Solid's Manufacturing Platform 1 © 2026 Solid Biosciences – Non-Confidential
Slide 13: Dual Plasmid Design Delivers a Significant Yield Increase
Solid’s Dual Plasmid Design Delivers a Significant Yield Increase Compared to Standard Triple Plasmid Transfection Solid Dual Plasmid Design Relative Yield Improvement Using Solid Dual Plasmid vs 3 Plasmid System* x x x x x x x 1.6-2.8x increase in upstream yields with Solid’s dual plasmid independe
Slide 14: Manufacturing Platform Can Enhance Safety and Reduce CoGS
By Increasing Yields and Purity, Solid’s Manufacturing Platform Has The Potential to Further Enhance Safety and Reduce CoGS High, consistent Efficient full Scalable to 500L yield & recovery capsid with identical across sites and enrichment performance scales >200 operating parameters defined between
Slide 15: Pioneering Best Practices to Continuously Innovate in CMC Excellence
Pioneering Best Practices to Continuously Innovate and Stay at the Forefront of CMC Excellence Solid Platform Improvements >Up to100x Platform yields are consistently high independent of capsid Improvement in Platform Yield or GOI (Platform iteration 4) Since PD Work Began Upstream Yield (vg/mL- ddP
Slide 16: Thank you
Thank you Please Contact BusinessDevelopment@SolidBio.com For Additional Information © 2025 Solid Biosciences - Confidential